The severe sole effects of seizures on the cortical part of bone were reported in our previous study. However, the side effects of anti-epileptic drug therapy on bones has not been differentiated from the effects of the convulsive seizures, yet. This study provides the first report on differentiation of the effects of seizures and carbamazepine (a widely used antiepileptic drug) therapy on bones; 50 mg/kg/day drug was given to genetically induced absence epileptic rats for five weeks. Distinct bone regions including cortical, trabecular, and growth plate in each of tibia, femur, and spine tissues were studied using Fourier transform infrared (FT-IR) imaging and Vickers microhardness test. Blood levels of vitamin D and bone turnover biomarkers were also measured. According to the FT-IR imaging results, both seizure and carbamazepine-treated groups, more dominantly the drug-treated group, had lower mineral content with altered collagen crosslinks and higher crystallinity, implying reduced bone strength. Lower microhardness values also supported lower mechanical strength in bones. The most affected bone tissue and region from seizures and treatment was found as the spine and cortical, respectively. While there was a reduction in vitamin D and calcium levels in both seizure and carbamazepin-treated groups, significantly elevated PTH and bone turnover biomarkers were only seen in the drug-treated group.
McHughJ.C.DelantyN.“Epidemiology and Classification of Epilepsy: Gender Comparisons”. Int. Rev. Neurobiol. 2008. 83: 11–26.
2.
DelorenzoR.SunaD.A.DeshpandL.S.“Cellular Mechanisms Underlying Acquired Epilepsy: The Calcium Hypothesis of the Induction and Maintenance of Epilepsy”. Pharmacol. Ther. 2005. 105: 229–266.
CoppolaG.FortunatoD.AuricchioG.MainolfiC.et al.“Bone Mineral Density in Children, Adolescents, and Young Adults with Epilepsy”. Epilepsia. 2009. 50(9): 2140–2146.
5.
AroraE.SinghH.GuptaY.K.“Impact of Antiepileptic Drugs on Bone Health: Need for Monitoring, Treatment, and Prevention Strategies”. J. Fam. Med. Prim. Care. 2016. 5(2): 248–253.
6.
CagirmazT.YapiciC.OrakM.M.GulerO.“Bilateral Femoral Neck Fractures After an Epileptic Attack: A Case Report”. Int. J. Surg. Case Rep. 2015. 6: 107–110.
7.
MintzerS.BoppanaP.ToguriJ.DesantisA.“Vitamin D Levels and Bone Turnover in Epilepsy Patients Taking Carbamazepine or Oxcarbazepine”. Epilepsia. 2006. 47(3): 510–515.
8.
ChouI.J.LinK.L.WangH.S.WangC.J.“Evaluation of Bone Mineral Density in Children Receiving Carbamazepine or Valproate Monotherapy”. Acta Paediatr. Taiwan. 2007. 48(6): 317–322.
9.
KimS.H.LeeJ.W.ChoiK.G.ChungH.W.et al.“A 6-Month Longitudinal Study of Bone Mineral Density with Antiepileptic Drug Monotherapy”. Epilepsy Behav. 2007. 10(2): 291–295.
10.
SalimipourH.KazerooniS.SeyedabadiM.NabipourI.et al.“Antiepileptic Treatment is Associated with Bone Loss: Difference in Drug Type and Region of Interest”. J. Nucl. Med. Technol. 2013. 41(3): 208–211.
11.
BaekJ.H.SeoY.H.KimG.H.KimM.K.et al.“Vitamin D Levels in Children and Adolescents with Antiepileptic Drug Treatment”. Yonsei Med. J. 2014. 55(2): 417–421.
12.
Gniatkowska-NowakowskaA.“Fractures in Epilepsy Children”. Seizure. 2010. 19(6): 324–325.
13.
ErbayatA.E.SerdarogluA.TumerL.GucuyenerK.et al.“Evaluation of Bone Mineral Metabolism in Children Receiving Carbamazepine and Valproic Acid”. J. Pediatr. Endocrinol. Metab. 2000. 13(7): 933–939.
14.
LandmarkC.J.RytterE.JohannessenS.I.“Clinical Use of Anti-Epileptic Drugs at a Referral Centre for Epilepsy”. Seizure. 2007. 16(4): 356–64.
15.
SitgesM.ChiuL.M.GuarnerosA.NekrassovV.“Effects of Carbamazepine, Phenytoin, Lamotrigine, Oxcarbazepine, Topiramate and Vinpocetine on Na+ Channel-Mediated Release of [3H] Glutamate in Hippocampal Nerve Endings”. Neuropharmacology. 2007. 52(2): 598–605.
HakamiT.O’BrienT.J.PettyS.J.SakellaridesM.et al.“Monotherapy with Levetiracetam Versus Older AEDs: A Randomized Comparative Trial of Effects on Bone Health”. Calcif. Tissue Int. 2016. 98(6): 556–565.
18.
BabayigitA.DirikE.BoberE.CakmakciH.“Adverse Effects of Antiepileptic Drugs on Bone Mineral Density”. Pediatr. Neurol. 2006. 35(3): 177–181.
19.
SouvereinP.C.WebbD.J.WeilJ.G.StaaT.P. Vanet al.“Use of Antiepileptic Drugs and Risk of Fractures: Case-Control Study Among Patients with Epilepsy”. Neurology. 2006. 66(9): 1318–24.
20.
FuleihanG.E.DibL.YamoutB.et al.“Predictors of Bone Density in Ambulatory Patients on Antiepileptic Drugs”. Bone. 2008. 43(1): 149–155.
21.
PhabphalK.GeaterA.LeelawattanaR.et al.“Prevalence and Risk Factors of Low Bone Mineral Density and 25-Hydroxyvitamin D Status in Young Healthy Epileptic Adult Patients in a Tropical Asian Country Taking Antiepileptic Drug”. Bone. 2009. 45(2): 232–237.
22.
RahimdelA.DehghanA.MoghadamM.A.ArdekaniA.M.“Relationship Between Bone Density and Biochemical Markers of Bone Among Two Groups Taking Carbamazepine and Sodium Valproate for Epilepsy in Comparison with Healthy Individuals in Yazd”. Electron. Physician. 2016. 8(11): 3257–3265.
23.
JetteN.LixL.MetgeC.PriorH.et al.“Association of Antiepileptic Drugs with Nontraumatic Fractures: A Population-Based Analysis”. Arch. Neurol. 2011. 68(1): 107–112.
24.
ShethR.WesolowskiC.JacobJ.PenneyS.et al.“Effect of Carbamazepine and Valproate on Bone Mineral Density”. J. Pediatr. 1995. 127(2): 256–262.
25.
AksoyA.SonmezF.M.DegerO.HosverI.et al.“The Effects of Antiepileptic Drugs on the Relationships Between Leptin Levels and Bone Turnover in Prepubertal Children with Epilepsy”. J. Pediatr. Endocrinol. Metab. 2011. 24(9–10): 703–708.
26.
EspinosaP.S.PerezD.L.AbnerE.RyanM.“Association of Antiepileptic Drugs Vitamin D and Calcium Supplementation with Bone Fracture Occurrence in Epilepsy Patients”. Clin. Neurol. Neurosurg. 2011. 113(7): 548–551.
27.
PackA.M.MorrellM.J.RandallA.McMahonD.J.et al.“Bone Health in Young Women with Epilepsy After One Year of Antiepileptic Drug Monotherapy”. Neurology. 2008. 70(18): 1586–1593.
28.
BeniczkyS.A.VikenJ.JensenL.T.AndersenN.B.“Bone Mineral Density in Adult Patients Treated with Various Antiepileptic Drugs”. Seizure. 2012. 21(6): 471–472.
29.
VerrottiA.GrecoR.LatiniG.MorgeseG.et al.“Increased Bone Turnover in Prepubertal, Pubertal, and Postpubertal Patients Receiving Carbamazepine”. Epilepsia. 2002. 43(12): 1488–1492.
30.
TsukaharaH.KimuraK.TodorokiY.OhshimaY.et al.“Bone Mineral Status in Ambulatory Pediatric Patients on Long-Term Anti-Epileptic Drug Therapy”. Pediatr. Int. 2002. 44(3): 247–253.
31.
PettyS.J.MilliganC.J.TodaroM.RichardsK.L.et al.“The Antiepileptic Medications Carbamazepine and Phenytoin Inhibit Native Sodium Currents in Murine Osteoblasts”. Epilepsia. 2016. 57(9): 1398–1405.
32.
VerottiA.CoppolaG.ParisiP.MohnA.et al.“Bone and Calcium Metabolism and Antiepileptic Drugs”. Clin. Neurol. Neurosurg. 2010. 112(1): 1–10.
33.
ShenC.ChenF.ZhangY.GuoY.et al.“Association Between Use of Antiepileptic Drugs and Fracture Risk: A Systematic Review and Meta-Analysis”. Bone. 2014. 64: 246–253.
34.
BeerhorstK.SchouwenaarsF.M.TanI.Y.AldenkampA.P.“Epilepsy: Fractures and the Role of Cumulative Antiepileptic Drug Load”. Acta Neurol. Scand. 2012. 125(1): 54–59.
35.
OnoderaK.TakahashiA.MayanagiH.WakabayashiH.et al.“Phenytoin-Induced Bone Loss and Its Prevention with Alfacalcidol or Calcitriol in Growing Rats”. Calcif. Tissue Int. 2001. 69(2): 109–116.
36.
OnoderaK.TakahashiA.SakuradaS.OkanoY.“Effects of Phenytoin and/or Vitamin K2 (Menatetrenone) on Bone Mineral Density in the Tibiae of Growing Rats”. Life Sci. 2002. 70(13): 1533–1542.
37.
GaripS.SahinD.SevercanF.“Epileptic Seizure-Induced Structural and Functional Changes in Rat Femur and Tibia Bone Tissues: A Fourier Transform Infrared Imaging Study”. J. Biomed. Opt. 2013. 18(11): 111409.
38.
BrzoskaM.M.Moniuszko-JakoniukJ.“Low-Level Lifetime Exposure to Cadmium Decreases Skeletal Mineralization and Enhances Bone Loss in Aged Rats”. Bone. 2004. 35: 1180–1191.
39.
KrushinskiL.V.MolodkinaL.N.FlessD.A.DobrokhotovaL.P.et al.“The Functional Studies of the Brain During Sonic Stimulation”. In: WelchB.L.WelchA.A. (eds). Physiological Effects of Noise, New York: Plenum Press, 1974, pp. 159–183.
GaripS.SevercanF.“Determination of Simvastatin-Induced Changes in Bone Composition and Structure by Fourier Transform Infrared Spectroscopy in Rat Animal Model”. J. Pharm. Biomed. Anal. 2010. 52(4): 580–8.
42.
PleshkoN.BoskeyA.MendelsohnR.“Novel Infrared Spectroscopic Method for the Determination of Crystallinity of Hydroxyapatite Minerals”. Biophys. J. 1991. 60(4): 786–793.
43.
PaschalisE.P.Di CarloE.BettsF.ShermanP.et al.“FT-IR Microspectroscopic Analysis of Human Osteonal Bone”. Calcif. Tissue Int. 1996. 59(6): 480–487.
44.
MendelsohnR.PaschalisE.P.BoskeyA.L.“Infrared Spectroscopy, Microscopy, and Microscopic Imaging of Mineralizing Tissues: Spectra-Structure Correlations from Human Iliac Crest Biopsies”. J. Biomed. Optic. 1999. 4(1): 14–21.
45.
PaschalisE.P.VerdelisK.DotyS.B.BoskeyA.L.et al.“Spectroscopic Characterization of Collagen Cross-Links in Bone”. J. Bone Miner. Res. 2001. 16(10): 1821–1828.
46.
ReyC.CollinsB.GoehlT.DicksonI.R.et al.“The Carbonate Environment in Bone Mineral: A Resolution-Enhanced Fourier Transform Infrared Spectroscopy Study”. Calcif. Tissue Int. 1989. 45(3): 157–164.
47.
BoivinG.BalaY.DoublierA.FarlayD.et al.“The Role of Mineralization and Organic Matrix in the Microhardness of Bone Tissue from Controls and Osteoporotic Patients”. Bone. 2008. 43(3): 532–538.
48.
GamsjaegerS.MendelsohnR.BoskeyA.L.Gourion-ArsiquaudS.et al.“Vibrational Spectroscopic Imaging for the Evaluation of Matrix and Mineral Chemistry”. Curr. Osteoporos. Rep. 2014. 12(4): 454–464.
49.
BoskeyA.L.DicarloE.PaschalisE.WestP.et al.“Comparison of Mineral Quality and Quantity in Iliac Crest Biopsies from High- and Low-Turnover Osteoporosis: An FT-IR Microspectroscopic Investigation”. Osteoporos. Int. 2005. 16(12): 2031–2038.
50.
FaibishD.OttS.M.BoskeyA.L.“Mineral Changes in Osteoporosis: A Review”. Clin. Orthop. Relat. Res. 2006. 443: 28–38.
51.
GadelataS.J.LandisW.J.BoskeyA.L.MendelsohnR.“Polarized FT-IR Microscopy of Calcified Turkey Leg Tendon”. Connect. Tissue Res. 1996. 34(3): 203–211.
52.
TimlinJ.A.CardenA.MorrisM.D.“Chemical Microstructure of Cortical Bone Probed by Raman Transects”. Appl. Spectrosc. 1999. 53(11): 1429–1435.
53.
CamachoN.P.RinnenthalerS.PaschalisE.P.MendelsohnR.et al.“Complementary Information on Bone Ultrastructure from Scanning Small Angle X-ray Scattering and Fourier-Transform Infrared Microspectroscopy”. Bone. 1999. 25(3): 287–293.
54.
HuangR.Y.MillerL.M.CarlsonC.S.ChanceM.R.“In Situ Chemistry of Osteoporosis Revealed by Synchrotron Infrared Microspectroscopy”. Bone. 2003. 33(4): 514–521.
55.
BonserR.H.C.“Longitudinal Variation in Mechanical Competence of Bone Along the Avian Humerus”. J. Exp. Bio. 1995. 198(Pt. 1): 209–212.
56.
HolickMF. “Shining Light on the Vitamin D: Cancer Connection IARC Report”. Dermatoendocrinol. 2009. 1(1): 4–6.
57.
KirH.M.GaripS.SahinD.ÖztaşB.“Effects of Carbamazepine on Serum Parathormone, 25- Hydroxyvitamin D, Bone Specific Alkaline Phosphatase, C-Telopeptide, and Osteocalcin Levels in Healthy Rats”. Bosn. J. Basic Med. Sci. 2012. 12(4): 240–244.
58.
MidzyanovskayaI.S.KuznetsovaG.D.VinogradovaL.V.ShatskovaA.B.et al.“Mixed Forms of Epilepsy in a Subpopulation of WAG/Rij Rats”. Epilepsy Behav. 2004. 5(5): 655–661.
59.
UbeyliE.D.IlbayG.SahinD.AtesN.“Analysis of Spike-Wave Discharges in Rats Using Discrete Wavelet Transform”. Comput. Bio. Med. 2009. 39(3): 294–300.
60.
BoskeyA.CamachoN.P.“FT-IR Imaging of Native and Tissue-Engineered Bone and Cartilage”. Biomaterials. 2007. 28(15): 2465–2478.
61.
LingY.RiosH.F.MyersE.R.LuY.et al.“DMP1 Depletion Decreases Bone Mineralization in Vivo: An FT-IR Imaging Analysis”. J. Bone Miner. Res. 2005. 20(12): 2169–2177.
62.
BouxseinM.L.“Non-Invasive Measurements of Bone Strength: Promise and Peril”. J. Musculoskelet. Neuronal. Interact. 2004. 4(4): 404–405.
63.
LeemingD.J.HenriksenK.ByrjalsenI.QvistP.et al.“Is Bone Quality Associated with Collagen Age?”. Osteoporos. Int. 2009. 20(9): 1461–1470.
64.
BohicS.ReyC.LegrandA.SfihiH.et al.“Characterization of the Trabecular Rat Bone Mineral: Effect of Ovariectomy and Bisphosphonate Treatment”. Bone. 2000. 26(4): 341–348.
65.
BinkleyN.KruegerD.LensmeyerG.“25-Hydroxyvitamin D Measurement, 2009: A Review for Clinicians”. J. Clin. Densitom. 2009. 12(4): 417–427.
DuboeufF.Burt-PichatB.FarlayD.SuyP.et al.“Bone Quality and Biomechanical Function: A Lesson from Human Ossicles”. Bone. 2015. 73: 105–110.
68.
SeemanE.DelmasP.D.“Bone Quality—The Material and Structural Basis of Bone Strength and Fragility”. N. Engl. J. Med. 2006. 354(21): 2250–2261.
69.
NagataK.“HSP47 As a Collagen-Specific Molecular Chaperone: Function and Expression in Normal Mouse Development”. Semin. Cell Dev. Biol. 2003. 14(5): 275–282.
70.
Viguet-CarrinS.GarneroP.DelmasP.D.“The Role of Collagen in Bone Strength”. Osteoporos Int. 2006. 17(3): 319–336.
71.
PaschalisE.P.TatakisD.N.RobinsS.FratzlP.et al.“Lathyrism-Induced Alterations in Collagen Cross-Links Influence the Mechanical Properties of Bone Material Without Affecting the Mineral”. Bone. 2011. 49(6): 1232–1241.
72.
LevasseurR.“Bone Tissue and Hyperhomocysteinemia”. Joint Bone Spine. 2009. 76(3): 234–240.
73.
BoyarH.ZorluF.MutM.SevercanF.“The Effects of Chronic Hypoperfusion on Rat Cranial Bone Mineral and Organic Matrix: A Fourier Transform Infrared Spectroscopy Study”. Anal Bioanal Chem. 2004. 379(3): 433–438.
74.
Gourion-ArsiquaudS.FaibishD.MyersE.SpevakL.et al.“Use of FT-IR Spectroscopic Imaging to Identify Parameters Associated with Fragility Fracture”. J. Bone Miner. Res. 2009. 24(9): 1565–1571.
75.
SaidF.Ghoul-MazgarS.RuhinB.AbdellaouiM.et al.“Mandibular Bone Alterations of Ovariectomized Rats Under Vitamin D Insufficiency”. Histol. Histopathol. 2008. 23(4): 479–485.
76.
U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General, Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004.
77.
SilverbergS.J.ShaneE.De La CruzL.DempsterD.W.et al.“Skeletal Disease in Primary Hyperparathyroidism”. J. Bone Miner. Res. 1989. 4(3): 283–291.
78.
RiggsB.L.KhoslaS.MeltonL.J.III. “Sex Steroids and the Construction and Conservation of the Adult Skeleton”. Endocr. Rev. 2002. 23(3): 279–302.
79.
SaagK.“Glucocorticoid-Induced Osteoporosis”. Endocrinol. Metab. Clin. North Am. 2003. 32(1): 135–157.
80.
AndersonH.SipeJ.HessleL.DhanyamrajuR.et al.“Impaired Calcification Around Matrix Vesicles of Growth Plate and Bone in Alkaline Phosphatase-Deficient Mice”. Am J. Pathol. 2004. 164(3): 841–847.
81.
SpiegelA.M.“Pathophysiology of Primary Hyperparathyroidism”. J. Bone Miner. Res. 1991. 6(2): S15–7; Discussion S31–2.
82.
EjerstedC.AndreassenT.T.OxlundH.JorgensenP.H.et al.“Human Parathyroid Hormone (1–34) and (1–84) Increase the Mechanical Strength and Thickness of Cortical Bone in Rats”. J. Bone Miner. Res. 1993. 8(9): 1097–1101.
83.
LoupyA.RamakrishnanS.K.WootlaB.ChambreyR.et al.“PTH-Independent Regulation of Blood Calcium Concentration by the Calcium-Sensing Receptor”. J. Clin. Invest. 2012. 122(9): 3355–3367.
84.
MatousekP.ClarkI.P.DraperE.R.C.MorrisM.D.et al.“Subsurface Probing in Diffusely Scattering Media Using Spatially Offset Raman Spectroscopy”. Appl. Spectrosc. 2005. 59(4): 1485–1492.
85.
DraperE.R.MorrisM.D.CamachoN.P.MatousekP.et al.“Novel Assessment of Bone Using Time-Resolved Transcutaneous Raman Spectroscopy”. J. Bone Miner. Res. 2005. 20(11): 1968–1972.
86.
MatousekP.StoneN.“Recent Advances in the Development of Raman Spectroscopy for Deep Non-Invasive Medical Diagnosis”. J. Biophotonics. 2013. 6(1): 7–19.
87.
BuckleyK.KernsJ.G.VintonJ.GikasP.D.et al.“Towards the in Vivo Prediction of Fragility Fractures with Raman Spectroscopy”. J. Raman Spectrosc. 2015. 46(7): 610–618.
88.
KaluD.N.“The Ovariectomized Rat Model of Postmenopausal Bone Loss”. Bone Miner. 1991. 15(3): 175–192.
89.
TurnerA.S.“Animal Models of Osteoporosis-Necessity and Limitations”. Eur. Cell. Mater. 2001. 1: 66–81.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
